The mutant histone H3 acts as a selective inhibitor of the PRC2 chromatin-modifying complex by binding and presumably sequestering it. PRC2 is heralded as a promising drug target, given its activity-enhancing alterations and aberrant upregulation in several types of cancer.
BrainBase
a curated knowledgebase for brain diseases
